By Kailyn Rhone
NeuroPace expects to report a rise in fourth quarter and full-year sales.
The Mountain View, Calif.-based medical device company gave preliminary fourth quarter results on Wednesday, and said it forecasts sales of $21 million to $21.5 million, an increase of 17% to 19%.
For the full fiscal year, NeuroPace said it now expects sales of $79.4 million to $79.9 million, up 21% to 22%. It previously guided for full-year sales to be $73 million to $77 million.
Cash and short-term investments as of Dec. 31 are expected to be $52.8 million.
NeuroPace said its Nautilus pivotal trial is on track to complete the required one year follow-up of subjects in March. It also anticipates the data lock and subsequent trial data analysis commencing in the second quarter.
Write to Kailyn Rhone at kailyn.rhone@wsj.com
(END) Dow Jones Newswires
January 08, 2025 17:02 ET (22:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.